SWIFT: Prospective 48-Week Study to Evaluate Efficacy and Safety of Switching to Emtricitabine/Tenofovir From Lamivudine/Abacavir in Virologically Suppressed HIV-1 Infected Patients on a Boosted Protease Inhibitor Containing Antiretroviral Regimen

Author： Campo R.   DeJesus E.   Bredeek U. F.   Henry K.   Khanlou H.   Logue K.   Brinson C.   Benson P.   Dau L.   Wang H.   White K.   Flaherty J.   Fralich T.   Guyer B.   Piontkowsky D.  

Publisher： Oxford University Press

ISSN： 1058-4838

Source： Clinical Infectious Diseases, Vol.56, Iss.11, 2013-06, pp. : 1637-1645

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Endothelial function in HIV-infected patients switching from a boosted protease inhibitor-based regimen to raltegravir: a substudy of the SPIRAL study

By Masiá Mar   Martínez Esteban   Padilla Sergio   Gatell José M.   Gutiérrez Félix  

Journal of Antimicrobial Chemotherapy, Vol. 68, Iss. 2, 2013-02 ,pp. : 409-413

Oxford University Press

Access to resources Recommend Favorite

Changes in Serum Markers of Inflammation and Endothelial Activation in HIV-Infected Antiretroviral Naive Patients Starting A Treatment with Abacavir-Lamivudine or Tenofovir-Emtricitabine Plus Efavirenz

By  

Current HIV Research, Vol. 14, Iss. 1, 2016-01 ,pp. : 61-70

Bentham Science Publishers

Access to resources Recommend Favorite

Switching to Raltegravir in Virologically Suppressed in HIV-1-Infected Patients: A Retrospective, Multicenter, Descriptive Study

By  

Current HIV Research, Vol. 10, Iss. 8, 2012-01 ,pp. : 673-678

Bentham Science Publishers

Access to resources Recommend Favorite

Impact of Different Antiretroviral Strategies on Total HIV-DNA Level in Virologically Suppressed HIV-1 Infected Patients

By  

Current HIV Research, Vol. 15, Iss. 6, 2018-01 ,pp. : 448-455

Bentham Science Publishers

Access to resources Recommend Favorite

Quadruple Nucleos(t)ide Reverse Transcriptase Inhibitors-Only Regimen of Tenofovir Plus Zidovudine/Lamivudine/Abacavir in Heavily Pre-Treated HIV-1 Infected Patients: Salvage Therapy or Backbone Only?

By  

Current HIV Research, Vol. 7, Iss. 3, 2009-05 ,pp. : 320-326

Bentham Science Publishers

Access to resources Recommend Favorite